<DOC>
	<DOC>NCT01019577</DOC>
	<brief_summary>The purpose of this study is to determine the response rates for Ixabepilone (BMS-247550) in subjects with metastatic breast cancer previously treated with an anthracycline and who are taxane resistant.</brief_summary>
	<brief_title>Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Women aged 20 years or older Patients with metastatic breast cancer whose primary lesion was definitely diagnosed to be breast by histological or cellular examination Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of â‰¥ 2</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>